Investigation launched into Immunovant officers for possible self-dealing harming shareholders
Kuehn Law, PLLC has initiated an investigation into potential breaches of fiduciary duties by officers and directors of Immunovant, Inc., citing possible self-dealing. This probe could lead to financial damages for shareholders and changes in the company's corporate governance. Long-term shareholders are encouraged to seek legal counsel promptly due to potential time limitations for action.
GSA Capital Partners LLP Takes $2.52 Million Position in Immunovant, Inc. $IMVT
GSA Capital Partners LLP has initiated a significant position in Immunovant, Inc. (NASDAQ:IMVT), purchasing 65,267 shares valued at approximately $2.52 million during the second quarter. This move comes as institutional investors and hedge funds collectively hold 47.08% of the company's stock, despite recent insider sales by the CTO and CEO to cover tax obligations. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $44.00, while the company recently missed earnings per share estimates but met revenue forecasts.
Assenagon Asset Management S.A. Has $639,000 Holdings in Immunovant, Inc. $IMVT
Assenagon Asset Management S.A. significantly reduced its stake in Immunovant, Inc. (NASDAQ:IMVT) by 91.9% in the second quarter, selling 188,642 shares and retaining 16,577 shares valued at approximately $639,000. Despite this, institutional investors collectively own 47.08% of the company, and analysts generally maintain a "Moderate Buy" rating with an average price target of $44. The article also details other institutional investor activity, recent analyst ratings, stock performance, and insider trading.
Dimensional Fund Advisors LP Sells 103,356 Shares of Immunovant, Inc. $IMVT
Dimensional Fund Advisors LP significantly reduced its stake in Immunovant, Inc. (NASDAQ:IMVT) by selling 103,356 shares, retaining 57,086 shares valued at $1.42 million. This comes as Immunovant's insiders, including the CTO and COO, also sold a substantial number of shares recently. Analysts currently rate Immunovant as a "Moderate Buy" with a consensus price target of $44.00, despite the company reporting a wider-than-expected quarterly loss.
Immunovant stock hits 52-week high at 41.37 USD
Immunovant Inc.'s stock reached a 52-week high of $41.37, reflecting a 169% total return over the past year and strong investor confidence. Despite this, InvestingPro analysis suggests the stock might be overvalued relative to its Fair Value. Separately, Roivant Sciences, a related entity, reported an EPS miss due to increased R&D spending, though its stock remained near its 52-week high.
The Manufacturers Life Insurance Company Cuts Stock Position in Immunovant, Inc. $IMVT
The Manufacturers Life Insurance Company reduced its stake in Immunovant, Inc. (NASDAQ:IMVT) by 47.1% in the first quarter, selling over 45,000 shares but retaining 51,421 shares valued at $1.28 million. Despite this, other institutional investors have increased their positions. Immunovant reported a wider-than-expected quarterly loss of $0.75 per share, though revenue matched estimates, and analysts maintain a "Moderate Buy" rating with an average target price of $44.00, even as company insiders sold shares totaling over $11 million.
Immunovant, Inc. (NASDAQ:IMVT) Given Average Rating of "Moderate Buy" by Analysts
Immunovant, Inc. (NASDAQ:IMVT) has received an average recommendation of "Moderate Buy" from ten analysts, with an average twelve-month price target of $44.00. Recent analyst reports show several price target increases and "buy" ratings. Insider transactions indicate recent sales by the COO and CTO, while institutional investors have adjusted their holdings, with some significantly increasing their stakes.
Liquidity Mapping Around (IMVT) Price Events
This article provides a liquidity mapping analysis for Immunovant Inc. (NASDAQ: IMVT), highlighting a near-term strong sentiment transitioning to mid-term neutrality and long-term positive bias. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis, identifying key support and resistance levels.
Hennion & Walsh Asset Management Inc. Has $4.65 Million Stock Holdings in Immunovant, Inc. $IMVT
Hennion & Walsh Asset Management Inc. significantly increased its stake in Immunovant, Inc. (NASDAQ:IMVT) by 32.6% in the second quarter, now holding 120,686 shares valued at $4.65 million. Despite this institutional confidence and a "Moderate Buy" consensus rating from analysts, Immunovant reported a wider-than-expected quarterly loss of $0.75 per share, and company insiders have sold substantial shares recently.
Renaissance Technologies LLC Invests $4.78 Million in Immunovant, Inc. $IMVT
Renaissance Technologies LLC has acquired a new stake of $4.78 million in Immunovant, Inc. (NASDAQ:IMVT), while institutional investors collectively own 47.08% of the company's stock. Despite analysts maintaining a "Moderate Buy" rating with an average target price of $44, Immunovant insiders have sold approximately $11.35 million in shares over the past three months, and the company recently missed quarterly EPS estimates. Immunovant is a clinical-stage biopharmaceutical company focusing on novel monoclonal antibody therapies for autoimmune diseases.
Immunovant, Inc. Q1 2027: Net loss $153.2M, EPS $(0.75) — 10-Q Summary
Immunovant, Inc. reported a net loss of $153.2 million for Q1 2027, an increase from $120.6 million in the prior year, with diluted loss per share at $(0.75). The company generated no revenues for the quarter and is focusing on the development of IMVT-1402 across multiple indications following the discontinuation of batoclimab. All IMVT-1402 studies are utilizing the commercial formulation and YpsoMate® autoinjector, with manufacturing contracts in place for clinical trials and potential launch.
Immunovant, Inc. Stock 12‑Month Price Target Raised to $47.56, Implies 21% Upside
Immunovant, Inc.'s stock price target has been increased to $47.56 from $47.06 by 16 analysts, implying a 21% potential upside based on its Aug. 5 closing price. The consensus rating remains "Buy," with 12 analysts recommending Buy and 4 recommending Hold.
Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress
Immunovant (IMVT) reported a wider-than-expected net loss of 75 cents per share in Q1 fiscal 2027, surpassing the Zacks Consensus Estimate of a 66-cent loss. Despite no approved products, the company is advancing its lead asset, IMVT-1402, an FcRn inhibitor, through multiple clinical trials for various autoimmune indications like Graves' disease and myasthenia gravis, with key data readouts anticipated in 2026 and 2027. Research and development expenses increased due to these clinical studies, but the company's cash reserves are projected to fund operations through the commercial launch of IMVT-1402 for Graves' disease.
Immunovant reports $153.2M net loss, $797.8M cash as of June 30, 2026
Immunovant reported a net loss of $153.2 million and held $797.8 million in cash as of June 30, 2026. The company's R&D expenses increased, while G&A expenses decreased. Immunovant confirmed that the clinical development timelines for IMVT-1402 across six indications remain on track, with potential registrational data expected through 2028, and a sufficient cash runway for the commercial launch of IMVT-1402 in Graves' disease.
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
Immunovant (Nasdaq: IMVT) announced its corporate updates and financial results for the first fiscal quarter ended June 30, 2026. The company's IMVT-1402 clinical development timelines remain on track across six indications, with topline data expected for various trials between calendar years 2026 and 2028. Immunovant reported a cash balance of $797.8 million, sufficient to fund operations through the potential launch of IMVT-1402 in Graves' disease.
Immunovant's $797.8M Cash Provides Runway to Potential Drug Launch
Immunovant (IMVT) reported its fiscal first-quarter 2026 financial results, including a net loss of $153.2 million and R&D expenses of $142.6 million. Despite increased R&D, the company's cash and cash equivalents of $797.8 million as of June 30, 2026, are projected to provide sufficient funding for the potential commercial launch of its IMVT-1402 drug for Graves’ disease. Immunovant confirmed that all clinical development timelines for IMVT-1402 across six indications remain on track, with key data readouts anticipated between late 2026 and 2028.
Earnings Flash (IMVT) Immunovant Posts Fiscal Q1 Loss $0.75 a Share, vs. FactSet Est of $0.65 Loss
Immunovant (IMVT) reported a fiscal Q1 loss of $0.75 per share, which is wider than the FactSet estimate of a $0.65 loss per share. The company is a clinical-stage immunology company focused on developing targeted therapies for autoimmune diseases. Its pipeline includes product candidates IMVT-1402 and batoclimab, targeting the neonatal FcRn.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of Class Action Lawsuit and Upcoming Deadline - IMVT; HSACU; HSAC; and HSACW
Pomerantz LLP has filed a class action lawsuit against Immunovant, Inc. (formerly Health Sciences Acquisitions Corporation) and some of its officers, seeking to recover damages for investors who purchased Immunovant securities between October 2, 2019, and February 1, 2021. The lawsuit alleges that Immunovant made materially false and misleading statements regarding its business, operations, and compliance policies, particularly concerning the safety and prospects of its drug candidate IMVT-1401, leading to a significant stock price drop. Shareholders who incurred losses have until April 20, 2021, to seek appointment as Lead Plaintiff.
Perceptive Advisors LLC Lowers Stake in Immunovant, Inc. $IMVT
Perceptive Advisors LLC reduced its stake in Immunovant, Inc. (NASDAQ:IMVT) by 19.9% in the first quarter of 2026, selling 397,507 shares but still retaining 1.60 million shares valued at approximately $39.7 million. Despite this, institutional investors collectively own 47.08% of the company. Immunovant shares opened at $38.62, near their 52-week high, while the company reported a larger-than-expected quarterly loss of $0.73 per share.
IMVT Maintained by JP Morgan -- Price Target Raised to $50.00
JP Morgan has maintained an Overweight rating on Immunovant (IMVT), increasing its price target to $50.00 from $47.00. Despite this positive analyst outlook, Immunovant holds a low GF Score™ of 29/100, indicating challenges in profitability and growth, and has seen significant insider selling. The company, a clinical-stage immunology firm, is focused on developing therapies for autoimmune diseases.
Immunovant (IMVT) Stock Forum and Discussion
This page provides a stock forum and discussion platform for Immunovant (IMVT). It allows investors and interested parties to share insights, opinions, and analysis related to the company's stock performance and future prospects. The forum serves as a community hub for active engagement on IMVT.
Immunovant (IMVT.US) will release its earnings report before the market opens on August 6.
Immunovant (IMVT.US) is scheduled to release its earnings report before the market opens on August 6. This announcement provides key information for investors and stakeholders anticipating the company's financial performance.
Immunovant (Nasdaq:IMVT) - Stock Analysis
This Simply Wall St analysis of Immunovant (IMVT) provides an overview of the company's financial health, future growth prospects, past performance, and insider transactions. It highlights the company's focus on developing targeted therapies for autoimmune diseases, particularly IMVT-1402, and discusses recent news, analyst ratings, and risks associated with the stock.
Why (IMVT) Price Action Is Critical for Tactical Trading
This article provides a critical analysis of Immunovant Inc. (IMVT) stock's price action for tactical trading, highlighting neutral near and mid-term readings but a positive long-term bias. It outlines distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strengths, support, and resistance levels to guide trading decisions.
Immunovant, Inc. Revenue Breakdown – NASDAQ:IMVT
This page provides financial overview for Immunovant, Inc. (NASDAQ: IMVT). It indicates that the market is closed with no trades. The article is primarily a navigation and information hub for financial data on Immunovant, Inc., mentioning sections like "Fundamentals and stats," "Overview," "Statements," "Statistics," and "Dividends."
Immunovant Inc (IMVT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Immunovant Inc (IMVT)'s dividend and stock split history. It states that the company has distributed a total of $0.00 in dividends over the past five years, indicating no recent dividend payouts. The page also presents other financial data like the stock price, market cap, and P/E TTM.
Immunovant Inc (IMVT) Cash Flow
This article provides a detailed cash flow statement for Immunovant Inc (IMVT), covering quarterly and annual data for operating, investing, and financing activities. It presents financial figures such as net income, capital expenditures, and free cash flow, alongside year-over-year percentage changes. The article also includes a FAQ section defining different types of cash flow and their significance for investors.
Immunovant Inc (IMVT) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Immunovant Inc (IMVT), listing major shareholders and their respective proportions, along with a breakdown by shareholder types. It also provides institutional shareholding data over several quarters and an overview of related ETF holdings. Key holders include Roivant Sciences Ltd., Fidelity Management & Research Company LLC, and Deep Track Capital LP.
Immunovant Inc (IMVT) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Immunovant Inc (IMVT), detailing analyst ratings and price targets. Based on 16 analysts, the current rating is "Buy" with a target price of USD 44.92, suggesting a 14.10% upside. The report also highlights past and future EPS expectations.
Immunovant Inc (IMVT) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Immunovant Inc (IMVT), covering key indicators like MACD, RSI, and Moving Averages. It summarizes the current signals for IMVT, indicating an overall neutral signal based on today's moving averages and other technical indicators. The analysis notes 5 buy signals and 1 sell signal from the moving averages (MA5 to MA200).
Form 4 Immunovant Inc For: 24 July By Investing.com
This article reports on the filing of Form 4 for Immunovant Inc. on July 24, as published by Investing.com. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report changes in beneficial ownership of the company's securities. The brief content indicates that there are no comments on this filing.
Form 4 Immunovant Inc For: 24 July By Investing.com
This article from Investing.com reports on a Form 4 filing for Immunovant Inc related to July 24. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of company insiders. The article includes the stock symbol IMVT and indicates a slight price change.
Affinity Asset Advisors LLC Sells 100,000 Shares of Immunovant, Inc. $IMVT
Affinity Asset Advisors LLC significantly reduced its stake in Immunovant, Inc. (NASDAQ:IMVT) by 50% in the first quarter of 2026, selling 100,000 shares and retaining 100,000 shares valued at approximately $2.48 million. This move comes as analysts have issued varied ratings, with a consensus "Hold" and an average price target of $39.70. Immunovant recently missed EPS estimates, and company insiders have also been selling shares, with the stock trading near its 52-week high.
Immunovant (IMVT) CTO sells 2,857 shares in mandated tax sell-to-cover
Immunovant's Chief Technology Officer, Jay S. Stout, sold 2,857 shares of common stock on July 23, 2026, at a weighted average price of $38.69 per share. This transaction was a mandated "sell-to-cover" to fulfill tax withholding obligations tied to the vesting of 6,250 restricted stock units. After the sale, Stout directly holds 205,341 shares of Immunovant common stock.
Immunovant CFO Tiago Girao sells $263,014 in company stock
Immunovant CFO Tiago Girao sold 6,798 shares of company stock for approximately $263,014 on July 23, 2026. This transaction was a "sell to cover" to meet tax withholding obligations for vested restricted stock units, not a discretionary sale. Following the sale, Girao still holds 240,798 shares, and the company's stock is trading near its 52-week high after a 115% return in the past year, with analysts maintaining positive ratings due to promising clinical trial results.
Immunovant CTO Jay Stout sells $110,537 in shares
Immunovant CTO Jay S. Stout sold 2,857 shares of the company's common stock for $110,537 to cover tax withholding obligations related to restricted stock units. This "sell to cover" transaction was a mandatory act as per company policy, not a discretionary sale. Immunovant shares are near their 52-week high, with significant analyst interest following positive trial data for IMVT-1402.
Immunovant CFO Tiago Girao sells $263,014 in company stock
Immunovant's CFO, Tiago Girao, sold 6,798 shares of company stock for approximately $263,014, a transaction primarily to cover tax withholding obligations on restricted stock units. This "sell to cover" action was mandated by company policy and not a discretionary sale. The sale occurred while IMVT shares were trading near their 52-week high, after a significant 115% return over the past year.
Immunovant director Atul Pande sells $59,699 in shares
Immunovant director Atul Pande sold 1,500 shares of the company's common stock for $59,699 on July 24, 2026, as part of a Rule 10b5-1 Plan. The sale occurred after he exercised stock options for the same number of shares at a lower price. Following these transactions, Pande directly owns 116,731 shares, with additional indirect and derivative holdings, while analysts continue to issue positive ratings for Immunovant due to promising clinical trial results.
Immunovant (NASDAQ: IMVT) CFO sells 6,798 shares to cover RSU taxes
Immunovant, Inc.'s CFO, Tiago Girao, sold 6,798 shares of common stock at a weighted average price of $38.69 per share on July 23, 2026. This transaction was a "sell to cover" to fund tax withholding obligations for 13,024 vested Restricted Stock Units (RSUs), leaving him with 240,798 shares. The sale was not a discretionary transaction but rather mandated by the company's policy for RSU tax satisfaction.
Immunovant CTO Jay Stout Executes Share Sale to Meet Tax Obligations Post-RSU Vesting
Immunovant's Chief Technology Officer, Jay Stout, sold company shares to fulfill tax obligations after his restricted stock units vested. This transaction offers insights for investors into the company's compensation and tax management strategies. The full article content is behind a login wall.
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
Immunovant, Inc. announced that it will report its financial results for the first quarter ended June 30, 2026, on Thursday, August 6, 2026, before market open. Roivant Sciences Ltd. will host a conference call and webcast at 8:00 a.m. ET on the same day, which will include a business update for Immunovant. Immunovant is a clinical-stage immunology company focused on developing therapies for autoimmune diseases.
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
Immunovant, Inc. (Nasdaq: IMVT) announced it will release its financial results for the first quarter ended June 30, 2026, on Thursday, August 6, 2026, before the market opens. Following this, Roivant Sciences Ltd. (Nasdaq: ROIV), Immunovant’s majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET to provide a business update, which will also cover Immunovant. Interested parties can register online for the conference call or find webcast details on Immunovant's investor relations website.
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
Immunovant, Inc. (Nasdaq: IMVT) announced it will report its first quarter financial results for the period ending June 30, 2026, on Thursday, August 6, 2026, before the market opens. Roivant Sciences Ltd. (ROIV), Immunovant's majority stockholder, will host a conference call and webcast at 8:00 a.m. ET on the same day to provide a business update, which will be accessible via online registration. Immunovant is a clinical-stage immunology company focused on developing therapies for autoimmune diseases.
Immunovant, Inc. ($IMVT) CEO 2026 Pay Revealed
Immunovant, Inc.'s CEO, Eric Venker, is estimated to have received $20,158,767 in compensation in 2026 based on a recent SEC filing. Insider trading activity for IMVT stock over the last 6 months shows 36 sales and zero purchases. Additionally, recent hedge fund activity indicates a mix of increased and decreased positions in IMVT, while analysts have set a median price target of $41.5.
Immunovant, Inc. SEC Filing (Jul 22, 2026)
This article reports on an ARS SEC filing by Immunovant, Inc. (IMVT) on July 22, 2026. The filing has a low impact and neutral sentiment according to AI analysis. The article also provides a summary of IMVT's stock overview, recent news, and other SEC filings.
Immunovant stock trades steady as cash reserves support ongoing autoimmune drug trials
Immunovant Inc. (IMVT) stock is stable due to significant cash reserves, which are funding ongoing clinical trials for its lead autoimmune drug, batoclimab. Despite minimal revenue and widening operating losses from high R&D spending, the company's substantial cash balance is expected to cover multiple years of expenses, reducing near-term financing risk. The market capitalization reflects the biotech's future potential, hinging on successful clinical outcomes for batoclimab, a FcRn-targeting antibody for various autoimmune diseases.
Law firm investigates Immunovant officers for possible self-dealing harming shareholders
Kuehn Law, PLLC is investigating whether officers and directors of Immunovant, Inc. violated their fiduciary duties through potential self-dealing. This probe could result in damages for shareholders and corporate governance reforms, prompting long-term Immunovant investors to seek legal consultation. The investigation highlights concerns regarding management integrity and the protection of shareholder value.
Understanding Momentum Shifts in (IMVT)
Immunovant Inc. (NASDAQ: IMVT) is showing neutral near and mid-term readings, potentially moderating a long-term positive bias. No clear price positioning or resistance levels above the current price suggest compelling upside potential. The article provides institutional trading strategies for various risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Form 4 Immunovant Inc For: 10 July By Investing.com
This article from Investing.com announces the filing of a Form 4 for Immunovant Inc. on July 10th. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's securities by an insider. The brief article provides no further details beyond the filing date.
Immunovant CTO Jay Stout sells $137,924 in IMVT stock
Immunovant's CTO, Jay Stout, sold 3,487 shares of IMVT stock totaling $137,924. These were "sell to cover" transactions to meet tax obligations from vested restricted stock units, not discretionary sales. The stock has seen a significant 135% gain over the past year, though InvestingPro analysis suggests it may be overvalued, while several analysts have raised price targets citing positive clinical trial results and improved sales outlooks.
